Table 1.

Neuroblastoma samples used in the study and ANN prognostic prediction

Sample label	Year of diagnosis	Sample source^*	Age at diagnosis (yrs)	INSS stage	MYCN amplification status	Shimada histology	COG risk stratification	Years of survival	All 37920 clonesave ANN vote	Top 19 genes ave ANN vote	ANN predicted outcome	Clinical outcome
NB1¹	1998	2	0.3	1	NA	F	L	5.1	—	0.02	A	A
NB2²	1997	2	0.9	4	NA	F	I	5.9	—	0.02	A	A
NB3³	1998	2	1.2	4	NA	F	H	5.7	—	0.01	A	A
NB4⁴	1997	2	1.4	4	NA	F	H	6.7	—	0.02	A	A
NB7	1998	2	1.3	1	NA	—	L	5.2	0.06	0.03	A	A
NB14	2000	2	0.9	4	AMP	—	H	3.2	0.18	0.05	A	A
NB15	1999	2	0.9	2	NA	—	L	3.9	0.03	0.02	A	A
NB18	2000	2	1.8	2	NA	—	L	1.4	0.72	0.95	D	D
NB21	2000	2	5.2	4	AMP	—	H	0.6	0.92	0.99	D	D
NB27	2000	2	10.5	4	AMP	UF	H	1.4	0.36	0.97	D	D
NB29¹	1998	2	0.3	1	NA	F	L	5.1	0.04	0.02	A	A
NB30²	1997	2	0.9	4	NA	F	I	5.9	0.05	0.01	A	A
NB31⁴	1997	2	1.4	4	NA	F	H	6.7	0.04	0.02	A	A
NB32³	1998	2	1.2	4	NA	F	H	5.7	0.05	0.02	A	A
NB61	1997	2	1.4	3	NA	F	I	6.3	0.22	0.2	A	A
NB69	1992	2	4.4	4	NA	—	H	0.5	0.16	0.8	D	D
NB75	1998	2	1	3	AMP	F	H	3	0.89	0.99	D	D
NB77	1994	2	0.2	1	NA	—	L	9.7	0.07	0.01	A	A
NB79	1997	2	2.8	4	AMP	—	H	1.5	0.9	0.99	D	D
NB205	1995	1	3.9	4	NA	—	H	2.3	0.52	0.84	D	D
NB207⁵	1995	1	4.4	4	NA	—	H	3.1	—	0.98	D	D
NB208	1995	1	0.8	1	NA	F	L	4.8	0.11	0.02	A	A
NB209⁶	1995	1	1.2	4	NA	UF	H	1	—	0.98	D	D
NB210⁷	1996	1	2.3	4	NA	UF	H	1.1	—	0.97	D	D
NB216	1996	1	0.6	3	NA	—	I	6.8	0.05	0.02	A	A
NB231	1998	1	0.5	2	NA	F	L	4	0.04	0.02	A	A
NB237	1999	1	4.1	1	NA	F	L	3.2	0.14	0.11	A	A
NB254	2000	3	2.6	4	AMP	—	H	1.8	0.88	0.98	D	D
NB255	1999	3	0.5	2	NA	—	L	4	0.71	0.24	A	A
NB266	1996	3	2	4	AMP	—	H	0	0.63	0.98	D	D
NB273⁵	1995	1	4.4	4	NA	—	H	3.1	0.84	0.96	D	D
NB275⁶	1995	1	1.2	4	NA	UF	H	1	0.94	0.99	D	D
NB276⁷	1996	1	2.3	4	NA	UF	H	1.1	0.57	0.98	D	D
NB278	1999	1	1.7	4	AMP	UF	H	0.8	0.85	0.94	D	D
NB283	1999	1	5.5	4	NA	UF	H	4	0.45	0.9	D	D
NB8	1998	2	4.6	4	NA	—	H	1.8	0.63	0.97	D	D
NB9	1996	2	1.1	1	NA	—	L	7.1	0.04	0.02	A	A
NB17	2000	2	1.2	1	NA	F	L	3.5	0.17	0.03	A	A
NB24	2000	2	0.6	4	NA	F	I	3	0.08	0.03	A	A
NB33	1998	2	1.4	1	NA	F	L	4.8	0.05	0.02	A	A
NB34	1997	2	1.2	1	NA	F	L	5.2	0.04	0.02	A	A
NB35	1997	2	2.6	4	NA	—	H	6.5	0.13	0.07	A	A
NB64	1998	2	0.6	4	NA	—	I	5.7	0.81	0.02	A	A
NB72	1994	2	3	3	AMP	—	H	1	0.94	0.98	D	D
NB201	1994	1	1.5	3	NA	UF	H	7.4	0.04	0.08	A	A
NB206	1995	1	3.3	4	NA	UF	H	5.8	0.82	0.96	D	D
NB215	1996	1	1.2	3	NA	F	I	7.3	0.04	0.03	A	A
NB220	1997	1	0.4	2	NA	F	L	6	0.06	0.04	A	A
NB221	1997	1	0.4	1	NA	F	L	5.7	0.09	0.02	A	A
NB232	1998	1	0.1	2	NA	F	L	4.3	0.06	0.04	A	A
NB235	1999	1	0.4	2	NA	F	L	3.2	0.15	0.03	A	A
NB238	1999	1	1.2	1	NA	F	L	3	0.04	0.02	A	A
NB251	2000	3	0.8	4	AMP	—	H	0.5	0.69	0.91	D	D
NB265	1996	3	1.8	4	AMP	—	H	2	0.78	0.97	D	D
NB269	1997	3	0.8	4	NA	—	I	5.3	0.04	0.07	A	A
NB282	1999	1	4.6	4	NA	UF	H	3.3	0.91	0.58	D	A

NOTE. All samples (except NB1, NB2, NB3, NB4, NB207, NB209, and NB210) were used in the leave-one-out ANN analysis. Samples highlighted in gray are the 21 test samples, and the rest were used for training in the clone optimization procedure. There were 7 replicated samples, marked by the numbers in superscript.

Abbreviations: INSS, International Neuroblastoma Staging System; AMP, amplification; NA, not amplified; F, favorable; −, not known; UF, unfavorable; COG, Children’s Oncology Group; H, high-risk; I, intermediate-risk; L, low-risk; ave ANN vote, average ANN committee votes; ANN prediction, average ANN vote <0.5 = A (alive) and >0.5 = D (dead); A, alive without event; D, deceased due to neuroblastoma disease.

Sample source: 1, Cooperative Human Tissue Network (Ohio); 2, German Cancer Research Center; 3, The Children’s Hospital at Westmead (Australia).